Pliafx® Prime

Mouldable Demineralised Fibres

Optimised Handling. Uncompromised Performance.

What is PliaFX Prime?

PliaFX Prime is 100% bone fibres, demineralised to encourage bone formation and healing. The fibres interlock, allowing the graft to become mouldable upon rehydration without the use of a carrier.1

What is the PliaFX Prime advantage?

100% bone grows more bone than DBMs containing a carrier, as demonstrated in literature.2,3 First- generation DBM putties contain a carrier, such as glycerol, solely to improve handling characteristics of the graft. The proportion of bone content in first-generation DBM putties can be as low as 17% by weight.4 LifeNet Health's mouldable fibre technology eliminates the need for a carrier, providing 100% bone.



Alkaline phosphatase (ALP) is a marker of the early stages of new bone formation

What makes PliaFX Prime versatile?

PliaFX Prime is primarily used as a standalone graft and can be used in combination with other biomaterials such as autograft, allograft, and/or fluid of surgeon's choice. The precision-machined fibres are designed to interlock with these biomaterials to improve their handling characteristics.5

Simulated autograft

Simulated autograft mixed with PliaFX Prime

Speak to your local Business Development Manager, for further information using the details below:

T: 01443 719 555
E: customerservice@hospitalinnovations.co.uk
W: www.hospitalinnovations.com

HOSPITAL INNOVATIONS

Pliafx® Prime

Ambient Storage*

Order Code	Volume	Shelf Life
BL-1800-00	0.5 cc	4 years
BL-1800-01	1.0 cc	4 years
BL-1800-02	2.5 cc	5 years
BL-1800-05	5.0 cc	5 years
BL-1800-10	10.0 cc	5 years

*While ambient room temperature has not been defined by regulatory bodies, LifeNet Health would recommend storage at 2°C to 37°C with excursions of less than 24 hours up to 40°C. If an excursion outside this range occurs, please contact LifeNet Health.

References

1. Data on file LifeNet Health ES-17-090
2.Data on file LifeNet Health TR-0446
3.Boyan BD, Ranly DM, McMillan J, et al. Osteoinductive Ability of Human Allograft Formulations. J Periodontol. September 2006.
4.Kay JF, Vaughan LM. Proportional osteoinduction of demineralized bone matrix graft materials. February 2004: AW-0204.1.
5. Data on file LifeNet Health ES-16-085

Speak to your local Business Development Manager, for further information using the details below:

T: 01443 719 555
E: customerservice@hospitalinnovations.co.uk
W: www.hospitalinnovations.com

Hospital Innovations Limited
Concept House
Talbot Green Business Park
Pontyclun
CF72 9FG

HOSPITAL INNOVATIONS